How many drugs treat Cystic fibrosis of the lung?

Drug Landscape tracks 8 marketed treatments for Cystic fibrosis of the lung (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/cystic-fibrosis-of-the-lung.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cystic fibrosis of the lung — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cystic fibrosis of the lung (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cystic fibrosis of the lung, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Symdeko (Copackaged)	TEZACAFTOR	Vertex Pharms		CFTR	2018-01-01
Kalydeco	IVACAFTOR	Vertex Pharms Inc	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	Cystic fibrosis transmembrane conductance regulator	2012-01-01
Cysteine Hydrochloride	CYSTEINE	Exela Pharma	Vitamin C [EPC]	Cystine/glutamate transporter	1986-01-01
Acetadote	Acetylcysteine	Bristol-Myers Squibb	Antidote	Glutathione levels; reactive metabolite of acetaminophen	1963-01-01
Kalydeco	Kalydeco	Concert Pharmaceuticals		Cystic fibrosis transmembrane conductance regulator
Acetylcystein	Acetylcystein	University Hospital, Strasbourg, France		Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase
L-cysteine	L-cysteine	Louisiana State University Health Sciences Center Shreveport	Amino acid derivative	Cystine/glutamate transporter
Acetadote	Acetadote	University of Texas Southwestern Medical Center		Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Cystic fibrosis of the lung
Bristol-Myers Squibb · 1 drug in Cystic fibrosis of the lung
Concert Pharmaceuticals · 1 drug in Cystic fibrosis of the lung
Exela Pharma · 1 drug in Cystic fibrosis of the lung
Louisiana State University Health Sciences Center Shreveport · 1 drug in Cystic fibrosis of the lung
University Hospital, Strasbourg, France · 1 drug in Cystic fibrosis of the lung
University of Texas Southwestern Medical Center · 1 drug in Cystic fibrosis of the lung
Vertex Pharms · 1 drug in Cystic fibrosis of the lung
Vertex Pharms Inc · 1 drug in Cystic fibrosis of the lung

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cystic fibrosis of the lung:

Cite this brief

Drug Landscape (2026). Cystic fibrosis of the lung — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cystic-fibrosis-of-the-lung. Accessed 2026-06-10.

Cystic fibrosis of the lung full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing